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Background: It is well established in studies across several countries that tobacco smoking is more prevalent
among schizophrenic patients than the general population. Electronic cigarettes are becoming increasingly popular
with smokers worldwide. To date there are no large randomized trials of electronic cigarettes in schizophrenic
smokers. A well-designed trial is needed to compare efficacy and safety of these products in this special population.
Methods/Design: Intervention: We have designed a randomized controlled trial investigating the efficacy and
safety of electronic cigarette. The trial will take the form of a prospective 12-month randomized clinical study to
evaluate smoking reduction, smoking abstinence and adverse events in schizophrenic smokers not intending to
quit. We will also monitor quality of life, neurocognitive functioning and measure participants’ perception and
satisfaction of the product.
Outcome measures: A ≥50% reduction in the number of cigarettes/day from baseline, will be calculated at each
study visit (“reducers”). Abstinence from smoking will be calculated at each study visit (“quitters”). Smokers who
leave the study protocol before its completion and will carry out the Early Termination Visit or who will not satisfy
the criteria of “reducers” and “quitters” will be defined “non responders”.
Statistical analysis: The differences of continuous variables between the three groups will be evaluated with the
Kruskal-Wallis Test, followed by the Dunn multiple comparison test. The differences between the three groups for
normally distributed data will be evaluated with ANOVA test one way, followed by the Newman-Keuls multiple
comparison test. The normality of the distribution will be evaluated with the Kolmogorov-Smirnov test. Any
correlations between the variables under evaluation will be assessed by Spearman r correlation. To compare
qualitative data will be used the Chi-square test.
Discussion: The main strengths of the SCARIS study are the following: it’s the first large RCT on schizophrenic
patient, involving in and outpatient, evaluating the effect of a three-arm study design, and a long term of
follow-up (52-weeks).
The goal is to propose an effective intervention to reduce the risk of tobacco smoking, as a complementary
tool to treat tobacco addiction in schizophrenia.
Trial registration: ClinicalTrials.gov, NCT01979796.
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It is well established in studies across several countries
that tobacco smoking is more prevalent among schizo-
phrenic patients than the general population [1]. For ex-
ample, in the US, 80% or more of schizophrenic patients
smoke, compared to approximately 20% of the general
population [2]. An increased rate of smoking among sub-
jects with schizophrenia contributes to multiple negative
health effects, including higher rates of coronary heart
disease, hypertension, respiratory disease and lung cancer
than in the general population [3]. Randomized clinical
trials of currently marketed smoking cessation products
(varenicline, bupropion, nicotine replacement therapy) in
schizophrenia have shown limited effects [4]. This sce-
nario is further complicated by the belief that quitting
smoking will worsen psychiatric symptoms, or that
these patients have little or no interest in quitting.
Moreover, the prescribing information for bupropion
and varenicline, two important first-line medications
for nicotine dependence, carry a black-box warning
highlighting an increased risk of psychiatric symptoms
and suicidal ideation in patients reporting any history
of psychiatric illness [5].
Electronic cigarettes (e-cigarettes) are becoming in-
creasingly popular with smokers worldwide. Users re-
port buying them to help quit smoking, to reduce
cigarette consumption, to relieve tobacco withdrawal
symptoms, and to continue having a smoking experi-
ence, but with reduced health risks [6]. A recent ran-
domized controlled trial (RCT), showed that smokers
not immediately willing to quit who used e-cigarettes sub-
stantially decreased daily cigarette consumption without
significant side effects [7]. In a prospective 12-month pilot
study, e-cigarettes were shown to substantially decrease
cigarette consumption without causing significant side
effects in schizophrenic smokers not intending to quit [8],
however, in a recent large randomized clinical trial of
e-cigarettes conducted in 300 smokers, side effects
that are commonly recorded during smoking cessation
trials using drugs for nicotine dependence were infre-
quently reported during the course of the study [7];
for example, at week-2, hunger, insomnia, irritability,
anxiety, and depression were reported by 6.5%, 4.0%,
3.5%, 3.0% and 2.0% of participants, respectively. More-
over, no serious adverse events (AEs) (that is, major
depression, abnormal behavior or any event requiring
an unscheduled visit to the family practitioner or hos-
pitalization) occurred during the study. Quitters also
reported improved quality of life, which could be used
to motivate attempts to quit by individuals with con-
cerns about what life will be like without cigarettes [9]
Some authors suggest the hypothesis that smoking causes
cognitive decline and loss of gray-matter tissue in the
brain over time [10].Research plan
To date there are no large randomized trials of e-
cigarettes in schizophrenic smokers. A well-designed
trial is needed to compare efficacy and safety of these
products in this special population.
Objectives
Primary
The primary outcome is the evaluation of the efficacy
and safety of a popular electronic cigarette brand. The
trial will take the form of a prospective 12-month ran-
domized clinical study to evaluate smoking reduction,
smoking abstinence and AEs in schizophrenic smokers
not intending to quit, experimenting with two different
nicotine strengths of e-cigarette.
Secondary outcomes
The secondary outcomes are to monitor AEs, quality of
life, neurocognitive functioning, and spirometry, and to




One hundred fifty-three schizophrenic regular smokers
will be recruited in three centers (Smoking Cessation
Centre University of Catania Medical Hospital; Psychiatric
Unit of University of Catania Medical Hospital; CTA
“Villa Chiara” Psychiatric Clinic) following placement of
advertisements in local newspapers and radio/television
network inviting them to try the e-cigarette to reduce the
risk of tobacco smoking. Each participating center will in-
clude 51 eligible smokers in the study. The study protocol
has been approved by the Ethical Committee of the
University of Catania (Record number 674; 30-05-2013) in
accordance with the Helsinki Declaration. Written infor-
med consent will be obtained by all participants.
Inclusion criteria are: 1) schizophrenic subjects (ac-
cording to DSM-IV-TR criteria) from Sicily (Italy),
who smoke tobacco cigarettes, in who are in the stable
phase of illness (no relapse/hospitalization and/or need to
change psychopharmacological treatment in the last
12 months); 2) smoked ≥10 factory-made cigarettes/day
for at least the past five years; 3) age 18 to 65 years; 4) in
good general health (absence of cancer, acute myocardial
infarction, unstable angina, severe cardiac arrhythmia, re-
cent cerebrovascular incident, or severe atherosclerosis);
5) not currently attempting to quit smoking or wishing to
do so in the next (a specific test will be included to check
their unwillingness to quit) 6 months; 6) committed to
follow the trial procedures.
Exclusion criteria are: 1) use of smokeless tobacco or
nicotine replacement therapy; 2) pregnancy or breast-
feeding; 3) current or recent (less than 1 year) history of
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bidities according to the Investigator’s clinical assessment
(for example, cancer, acute myocardial infarction, unstable
angina, severe cardiac arrhythmia, recent cerebrovascular
incident, or severe atherosclerosis.
Products tested: electronic cigarette
The e-cigarette will be used in this study. It is a dispos-
able model that closely resembles the shape of a tobacco
cigarette. Its heating element in the atomizer is activated
by a rechargeable 3.7-V, 120mAh, lithium-ion battery.
Standard performance guarantees the equivalent of 300
to 400 puffs/each disposable product. The e-cigarette
contains a liquid solution of vegetable glycerin in which
nicotine or an aroma is dissolved. Two different types of
disposable e-cigarette will be provided for the study;
high-nicotine (with 24 mg nicotine) and no-nicotine
(with a tobacco aroma). Detailed toxicology and nicotine
content analyses of the e-cigarette has been provided to
the local ethics review boards (ERBs) (Figure 1).
Products tested: the PAIPO nicotine-free inhalator
(EchosSrl, Milan, Italy)
This plastic device resembles a cigarette and is intended
to replace some of the rituals associated with smoking
gestures, for example, the hand-to-mouth action of smok-
ing, and handling and manipulation of cigarettes. The
plastic device contains a sponge filter soaked in natural oil
enriched with extracts of different aromas. For this
study protocol we will provide a placebo grapefruit-flavor
PAIPO inhalator (Figure 2).
Study design
The study is a three-arm, randomized controlled, clinical
trial designed to assess the efficacy and safety of the e-Figure 1 Electronic cigarette. It is a disposable model that closely resem
120mAh, lithium-ion battery. The electronic cigarette contains a liquid solucigarette with 24 mg nicotine, the e-cigarette with no
nicotine, and the PAIPO nicotine-free inhalator. We
adhered to Consolidated Standards of Reporting Trials
(CONSORT) guidelines in the design of the trial.
At screening the diagnosis of schizophrenia will be
determined using the structured clinical interview for
DSM-IV axis I disorders - clinical version (SCID-I-CV);
subjects with organic psychosis, learning disabilities or
requiring a translator because of lack of Italian fluency
will be excluded from the study. The psychopathological
status of the participants will be assessed by a trained
psychiatrist (blinded to the treatment conditions) using
the positive and negative syndrome scale (PANSS) to
evaluate the severity of illness. Written informed consent
will be obtained by all eligible participants at this visit.
Screening in brief is as follows: informed consent; in-
clusion/exclusion criteria; Case Report Form”CRF (socio-
demographic factors; smoking history; SCID-I-CV; PANSS);
if eligible book next appointment in 1 week.
At baseline (BL), participants will be randomized into
three separate study groups. The randomization se-
quence will be computer generated by permuted blocks
of five for each of the three study conditions (A, B, and
C). Participants randomized in study group A will re-
ceive a 12-week supply of the e-cigarette with 24 mg of
nicotine; those in study group B, a 12-week supply of
the e-cigarette 0 mg of nicotine; participants in study
group C will receive a 12-week supply of the PAIPO
nicotine-free inhalator. A prospective evaluation of effi-
cacy and safety will be repeated at an additional follow-
up visit at 24 weeks. The study will consist of a total of
seven visits: a screening visit, a BL visit and five follow-
up visits (at weeks 4, 8, 12, 24, and 52). Three telephone
contacts (TC) will be scheduled during the treatment
phase (at weeks 2, 6, and 10) (Figure 3).bles the shape of a tobacco cigarette, with a rechargeable 3.7-V,
tion of vegetable glycerin in which nicotine or an aroma is dissolved.
Figure 2 The PAIPO nicotine-free inhalator (EchosSrl, Milan, Italy).
It is a plastic device that resembles a cigarette and is intended to
replace some of the rituals associated with smoking gestures. The
plastic device contains a sponge filter soaked in natural oil enriched
with extracts of different aromas.
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Participants will attend their study visits at the smoking
cessation clinic at approximately the same time of day.
With the exception of the BL study day, most visits will
take approximately 10 to 15 minutes to complete. The
BL visit will be carried out within seven days of the
screening visit. At BL (study visit 1), socio-demographic
factors, and detailed smoking history will be annotated
and individual pack-years (pack/yrs) calculated, together
with the ratings of quality of life and neurocognitive
functioning assessed by the quality of life scale (QLS)
and brief assessment of cognition in schizophrenia (BACS),
respectively. Physical cigarette dependence and behavioral
dependence will be measured with the Fagerstrom test for
cigarette dependence (FTCD) and Glover-Nilsson smoking
behavioral questionnaire (GN-SBQ), respectively. Addi-
tionally, levels of carbon monoxide in exhaled breath
(eCO) will be measured using a portable device (Micro
CO, Micro Medical Ltd, Kent, UK). Vital signs (heart rateFigure 3 Study design. The study is a three-arm, randomized controlled,
with 24 mg nicotine, the e-cigarette with no (0 mg) nicotine and the PAIPO(HR) and blood pressure (BP)), body weight, spirometry,
and AEs will also be recorded at baseline.
Participants will be given a free supply of e-cigarettes
or PAIPO inhalators (on average, a 4-week supply of
e-cigarettes) and instructed on how to correctly use
them. Key trouble-shooting support will be provided
and phone numbers will be supplied for medical as-
sistance. A full 4-week supply of nicotine or no-nicotine
e-cigarettes, or PAIPO inhalators (depending on the
study-arm allocation) will be also provided so that every
participant will have enough disposable products for each
study period; a study diary recording will be used to check
for the most common AEs related to the use of e-
cigarettes (for example, dry cough, mouth irritation, throat
irritation, headache, shortness of breath, nausea et cetera).
No emphasis on encouragement, motivation and reward
for the smoking cessation effort will be provided, because
this study was intended to monitor schizophrenic smokers
who are unwilling to quit. Participants will be instructed
to return every four weeks to obtain their 4-weekly supply
of e-cigarettes or PAIPO inhalators.
The BL (visit 1) in brief is as follows: CRF (physical
examination, FTCD, GN-SBQ, QLS, BACS, HR, BP,
weight, eCO, spirometry, AEs); craving/visual analog scale
(VAS); MNWS; randomization into either study group A
(e-cigarette 24 mg), B (e-cigarette 0 mg), or C (PAIPO); dis-
pense 4-weeks supply of nicotine e-cigarette, no-nicotine e-
cigarette or PAIPO inhalator (depending on the study-arm
allocation); dispense 4-week study diary for AEs; book for
next appointment in 4 weeks (week 4; study visit 2).
By and large, at week 4 (study visit 2), and week 8
(study visit 3), participants will a) receive further study
diaries for the residual study periods; b) have their
eCO levels and vital signs recorded; and c) returnclinical trial designed to assess the efficacy and safety of the e-cigarette
nicotine-free inhalator.
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the end of the week-12 study visit, no more products will
be provided by the investigators.
Week-4 (visit 2) in brief is as follows: collect 4-week
study diary for AEs; CRF (number of cigarettes/day,
eCO, HR, BP); craving/VAS; MNWS; PANSS; smokers’
product preference survey; dispense next 4-week supply
of nicotine e-cigarette, no-nicotine e-cigarette or PAIPO
inhalator (depending on the study-arm allocation);
dispense next 4-week study diary for AEs; book for next
appointment in 4 weeks (week 8; study visit 3).
Week-8 and -12 (visits 3 and 4) in brief are as follows:
collect 4-week study diary for AEs; CRF (number of
cigarettes/day, eCO, HR, BP); craving/VAS; MNWS;
PANSS; smokers’ product preference survey; dispense
next 4-week supply of nicotine e-cigarette, no-nicotine
e-cigarette or PAIPO inhalator (depending on the study-
arm allocation); book for next appointment in 12 weeks
(week24; study visit 5).
Week 24 (visit 5) in brief is as follows: collect 4-week
study diary for AEs; CRF (number of cigarettes/day,
eCO, HR, BP); craving/VAS; MNWS; PANSS; BACS;
QLS; smokers’ product preference survey; spirometry;
book for next appointment for the final visit (week 52;















Randomization into either study group A (Ecig 24 mg),
B (Ecig o mg), or C (paipo)
X
Dispense 4-weeks supply of either nicotine or no-nicotine
or paipo (depending on arm allocation)
X
Dispense 4-weeks’ study diary for AEs X
Spirometry X
Book for next appointment in 4 weeks (week-4; study visit 2) X
Craving/VAS X
MNWS X
PANSSWeek 52 (visit 6) in brief is as follows: CRF (number
of cigarettes/day, eCO, HR, BP); craving/VAS; MNWS;
PANSS; BACS; QLS; smokers’ product preference survey;
spirometry.
Study participants will attend a final follow-up visit at
week 52 to report product use and the number of any
tobacco cigarettes smoked (from which reduction and
quit rates could be calculated), and to re-check eCO
levels. Quality of life, neurocognitive functioning and
psychopathological status will be assessed by QLS, BACS,
and PANSS, respectively. Vital signs (HR and BP), body
weight, and spirometry will be recorded again as well as
participants’ perceptions of the specific product they are
using [11].
Early termination visit (unscheduled visit) is as follows:
CRF (number of cigarettes/day, eCO, HR, BP); craving/
VAS; MNWS; PANSS; BACS; QLS; smokers’ product
preference survey; spirometry (Table 1).
Study outcome measures
A reduction ≥50% in the number of cigarettes/day from
BL, defined as self-reported reduction in the number of
cigarettes/day (≥50%) compared to BL (together with an
eCO levels reduction, to objectively document a reduc-
tion from baseline), will be calculated at each study visitWk4 Wk8 Wk12 Wk24 Wk52 Early termination visit
Visit 2 Visit 3 Visit 4 Visit 5 Visit 6
X X X X X X
X
X X X X
X X X X X X
X X X X X X
X X
X X X X X X
X X X (x3)
X X X (x3)
X X X X
X X X (x3) X(x6)
X X X X X X
X X X X X X
X X X X X X
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defined as complete self-reported abstinence from tobacco
smoking - not even a puff (together with an eCO con-
centration ≤7 ppm), will be calculated at each study visit
(referred to as quitters). Smokers who do not satisfy the
criteria of reducers or quitters will be defined non re-
sponders. Smokers who leave the study protocol before its
completion due to lack of efficacy or poor tolerability of
the product under investigation, will carry out the early
termination visit and will be defined as non responders.
AEs, symptoms thought to be related to tobacco smok-
ing and e-cigarette use, and to withdrawal from nicotine,
will be annotated at BL and at each subsequent study visit
on the AE page of the study diary. Vital signs will be also
recorded. The number and the percentage of subjects
experiencing AEs, adverse reactions, serious AEs and AEs
leading to study withdrawal will be summarized by treat-
ment group. AEs will also be summarized by system organ
class and preferred term using the MedDRA dictionary.
Quality of life, neurocognitive functioning and psycho-
pathological status will be reassessed by QLS, BACS and
PANSS, respectively. Participants’ perceptions and liking
of the product will be assessed by asking them to rate
their levels of satisfaction with the products compared
to their own cigarettes using a VAS, scoring from 0 to
10 points (0 = completely unsatisfied, 10 = fully satisfied).
Using the same scale, they will also rate how much they
miss their own brand (0 = did not miss it at all, 10 =
missed it too much) and whether they would recommend
it to a friend/relative (0 = not recommended at all, 10 = ab-
solutely recommended).
Sample size
All statistical tests were two-tailed and were considered
to be statistically significant at P < 0.05. A sample size of
133 subjects was calculated accepting the following pa-
rameters: effect size medium = 0.30; alpha = 0.05; 1-ß =
0.80. Considering a drop-out rate of 15%, a total sample
size of 153 smokers was determined. The smokers will
be randomized into the three arms of our study protocol
(51 smokers for each arm).
Statistical methods
Statistical analysis will be performed with SPSS 20.0
(Statistical Package for Social Sciences Program, IBM).
Continuous variables will be described with mean,
standard deviation, median, minimum, maximum and
the 25th and 75th percentiles. Categorical variables will
be described with percentages and absolute frequencies.
The differences in continuous variables between the
three groups will be evaluated with the Kruskal-Wallis
test, followed by the Dunn multiple comparison test.
The differences between the three groups for normally
distributed data will be evaluated with one-way analysisof variance (ANOVA), followed by the Newman-Keuls
multiple comparison test. The normality of the distribu-
tion will be evaluated with the Kolmogorov-Smirnov test.
Any correlation between the variables under evaluation
will be assessed by Spearman r correlation. To compare
qualitative data we will use the Chi-square test with the
Yates correction or the Fisher exact test.
Discussion
People with schizophrenia have more than five times the
odds of current smoking and smoking cessation rates
are much lower than in the general population [12]. In
addition, smokers with schizophrenia smoke more heavily
and extract more nicotine from each cigarette [13]. Even
patients with first-episode psychosis tend to have high
prevalence of tobacco use and are much more likely to
smoke than age-matched controls, as confirmed in a
recent meta-analysis (odds ratio = 6.04) [14].
Chronic cigarette smoking has been suggested as a
major contributing factor to higher morbidity and mor-
tality in schizophrenic patients, especially in people aged
35 to 54 years [15]. In addition to such adverse health ef-
fects, cigarette smoking clearly represents a huge financial
burden on patients with schizophrenia. Money spent on
cigarettes is not being spent on clothing, leisure pursuits
and personal possessions, which could help to increase
the quality of life of these patients [16].
Through their smoking habits people with schizophre-
nia are contributing substantially to the cost of their
own care (those who smoke return 18 to 31% of their
benefits to the Treasury) [17]. However, heavy smoking
in schizophrenia cannot simply be viewed as a bad habit.
Rather, self-medication of clinical symptoms and side
effects of antipsychotic drugs appear to play a major role
[18]. The cognitive approach to the self-medication hy-
pothesis maintains that patients smoke in an attempt to
improve their cognitive deficits. Nicotine improves defi-
cits in attention and working memory in schizophrenic
patients even in first episode [19-22].
Healthcare providers previously have not offered
tobacco dependence treatment to patients with schizo-
phrenia, probably secondarily to stigma or lack of infor-
mation [23]. Moreover, smokers with schizophrenia have a
more severe nicotine dependence compared to smokers
without schizophrenia [14]. Hence, interventions may not
be as effective as they have been shown to be in the
general population. We also need to consider the
safety of these interventions, particularly in relation
to drug therapy. In addition, nicotine withdrawal can
cause symptoms such as depression, anxiety and irrit-
ability. All these factors may contribute to changes in
the mental state of these patients, and the extent of
these changes remains unclear [24]. For these reasons,
recent initiatives have aimed to study smoking habits
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schizophrenia [7,8,15,24].
The proposed randomized trial consists of an investiga-
tion of the efficacy and safety of e-cigarettes in schizo-
phrenic smokers. To date there are no large randomized
trials of e-cigarettes in schizophrenic smokers. The main
strengths of the SCARIS study are the following: it is the
first large RCT on schizophrenic patients, involving inpa-
tients and outpatients, with a three-arm study design and
long-term follow up (52 weeks).
The goal is to propose an effective intervention to reduce
the risk of tobacco smoking, as a complementary tool to
treat smokers with schizophrenia. Therefore, as our clinical
experience in the smoking cessation/reduction treatment of
smokers suffering of schizophrenia evolves, the smoking
cessation and reduction in schizophrenia (SCARIS) study
protocol stands as a unique milestone robust trial, which
will contribute to our fundamental understanding of the role
of the e-cigarette in smoking cessation/reduction and its in-
fluence on the health status of this particular population.
Trial status
We expect to start recruiting participants in September
2014.
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